Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Continuous glucose monitoring (CGM) is developing into an increasingly useful tool for glucose monitoring and therapeutic guidance in the treatment of diabetes. Multiple daily doses of insulin (MDI) is the most common method for intensive insulin treatment of type 1 diabetes and is also becoming more common in the treatment of type 2 diabetes as an increasing population with type 2 diabetes experiences progressive beta cell loss. The clinical evidence demonstrating the benefit of CGM in the outcomes of patients treated with MDI is becoming clearer, particularly with the recent completion of several randomized clinical trials addressing both type 1 and 2 diabetes. This evidence is reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 1×
“5-fold increase in cardiovascular death and in major cardiovascular events in those with type 2 diabetes in the ADVANCE Trial who experienced severe hypoglycemia.(62) Increased arrhythmias have been shown with hypoglycemia and multiple mechanisms have been proposed for hypoglycemia-induced cardiovascular events, inclu…”
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 3×
“002.(42) The GOLD trial used a crossover design with half of the 161 randomized participants using CGM for 6 months in addition to SMBG, followed by a 4-month washout period, then 6 months of usual care with SMBG alone, whereas the other half of the participants performed SMBG for the initial 6 months, and washout per…”
Self-citationGlycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 1×
“found no difference in HbA1c after 6 months, but did find nearly 30 min less time daily in the hypoglycemic range in those on the sensor.(76) However, flash glucose sensing differs from CGM in frequency of results, automated trending information, and the use of alarms.”
Miller, K. M., Beck, R. W., Bergenstal, R. M., Goland, R. S., Haller, M. J., McGill, J. B., Rodriguez, H., Simmons, J. H., Hirsch, I. B., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1770 · Cited by 505
Self-citationYeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435 · cited 1×
“4,5 8 Patients are faced with numerous barriers to improved control, including in-convenience, cost, inertia in changing personal health habits, fear of weight gain, and fear of hypoglycemia.”
Self-citationvan Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
Murphy, H. R., Rayman, G., Lewis, K., Kelly, S., Johal, B., Duffield, K., Fowler, D., Campbell, P. J., & Temple, R. C. (2008) · BMJ · doi:10.1136/bmj.a1680 · Cited by 358 · cited 1×
“showed several benefits of CGM in patients with type 1 or 2 type diabetes during pregnancy.(74) A pilot study evaluated the benefit of CGM in type 2 patients with ESRD receiving hemodialysis and being treated with MDI.”
Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013
Lipska, K. J., Yao, X., Herrin, J., McCoy, R. G., Ross, J. S., Steinman, M. A., Inzucchi, S. E., Gill, T. M., Krumholz, H. M., & Shah, N. D. (2017) · Diabetes Care · doi:10.2337/dc16-0985 · Cited by 306
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250 · cited 1×
“Likewise, the Endocrine Society and the American Association of Clinical Endocrinologists support CGM use in type 1 diabetes.(13,14) However, as noted”
Self-citationYoo, H. J., An, H. G., Park, S. Y., Ryu, O. H., Kim, H. Y., Seo, J. A., Hong, E. G., Shin, D. H., Kim, Y. H., Kim, S. G., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.06.015 · Cited by 244 · cited 1×
“studied 65 patients with poorly controlled T2D on a variety of treatments.(48) The focus of the CGM was on education and promotion of lifestyle changes and resulted in a 0.”
Little, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Chapple, O., Lubina-Solomon, A., Chadwick, T. J., Barendse, S., Stocken, D. D., Brennand, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0030 · Cited by 237
Tanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Mauras, N., Beck, R., Xing, D., Ruedy, K., Buckingham, B., Tansey, M., White, N. H., Weinzimer, S. A., Tamborlane, W., Kollman, C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1746 · Cited by 204
Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500320 · Cited by 199 · cited 1×
“studied 100 patients with type 2 diabetes using realtime CGM for 2 of every 3 weeks over a 12-week period in a randomized controlled trial.(68) The authors reported a 0.”
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195 · cited 1×
“Likewise, the Endocrine Society and the American Association of Clinical Endocrinologists support CGM use in type 1 diabetes.(13,14) However, as noted”
Mortality in type 1 diabetes in the DCCT/EDIC versus the general population
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-2399 · Cited by 194
Allen, N. A., Fain, J. A., Braun, B., & Chipkin, S. R. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.01.006 · Cited by 182 · cited 1×
“reported significantly improved HbA1c with a behavioral approach that resulted in weight loss and increased physical activity.(47) Yoo et al.”
Bailey, T. S., Zisser, H. C., & Garg, S. K. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0205 · Cited by 159 · cited 2×
“completed a 12-week observational trial in 140 adults with type 1 or type 2 diabetes.(32) Among the 57 total patients on MDI (23 with type 2 DM) the reduction in HbA1c was 0.”
Wright, A. D., Cull, C. A., Macleod, K. M., & Holman, R. R. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.08.010 · Cited by 153
The FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
Cariou, B., Fontaine, P., Eschwege, E., Lièvre, M., Gouet, D., Huet, D., Madani, S., Lavigne, S., & Charbonnel, B. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.007 · Cited by 129
Novodvorsky, P., Bernjak, A., Chow, E., Iqbal, A., Sellors, L., Williams, S., Fawdry, R. A., Parekh, B., Jacques, R. M., Marques, J. L. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2177 · Cited by 111
Causes of death in childhood‐onset Type 1 diabetes: long‐term follow‐up
Gagnum, V., Stene, L. C., Jenssen, T. G., Berteussen, L. M., Sandvik, L., Joner, G., Njølstad, P. R., & Skrivarhaug, T. (2017) · Diabetic Medicine · doi:10.1111/dme.13114 · Cited by 87 · cited 1×
“Sudden death, including those discovered dead-in-bed accounted for 22% of the deaths in persons dying under age 40 with type 1 diabetes in the Australian study and 5% of those dying before age 30 in the Norwegian cohort.(21,24) One case report confirmed hypoglycemia as the cause of deadin-bed syndrome, and a recent re…”
Garg, S. K., Voelmle, M. K., Beatson, C. R., Miller, H. A., Crew, L. B., Freson, B. J., & Hazenfield, R. M. (2011) · Diabetes Care · doi:10.2337/dc10-1852 · Cited by 85
Continuous glucose monitoring in patients with type 1 diabetes using insulin injections
Foster, N. C., Miller, K. M., Tamborlane, W. V., Bergenstal, R. M., & Beck, R. W. (2016) · Diabetes Care · doi:10.2337/dc16-0207 · Cited by 76 · cited 3×
“41 Two studies published in 2017 have addressed the questions of overall effectiveness of CGM in improving glycemic control in type 1 diabetes patients using MDI, including lowering of HbA1c, time in range, and time spent in hypo-glycemia.”
Influential
Cited by
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“with or without alarms for hyper- and hypoglycemic excursions and events (284).”
BackgroundSelf-citationParis, I., Henry, C., Pirard, F., Gérard, A., & Colin, I. M. (2018) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.23 · Cited by 84
Lin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Metadata
- Authors
- McGill, J. B., & Ahmann, A.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-06
- Volume
- 19
- Issue
- S3
- Pages
- S-3-S-12
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2622511551
- Cited by
- 49
- References
- 33
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.